A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Takayasu syndrome
  • Focus Therapeutic Use
  • Acronyms TAKT study
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 09 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2017 Primary endpoint (Time to relapse of Takayasu Arteritis) has not been met as per the results published in the Annals of the Rheumatic Diseases
    • 30 Nov 2017 Results published in the Annals of the Rheumatic Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top